Hyperlipidemia Type 3 Treatments

Find Hyperlipidemia Type 3 Treatments

Generic Name

Rosuvastatin

Brand Names

Crestor, Rosuvastain

FDA approval date: July 19, 2016

Classification: HMG-CoA Reductase Inhibitor

Form: Tablet

What is Crestor (Rosuvastatin)?

CRESTOR is indicated: To reduce the risk of major adverse cardiovascular events in adults at increased risk for CV events., As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol : ∘ in adults with hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia . ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia. CRESTOR is an HMG Co‑A reductase inhibitor indicated: , To reduce the risk of major adverse cardiovascular events in adults at increased risk for CV events., As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol : ∘ in adults with primary hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia . ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia ., As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

STAT-CAT: Statin Therapy to Prevent Cancer Associated Venous Thromboembolism

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20...

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

Enrollment Status: Recruiting

Publish Date: June 12, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a...

View All Clinical Trials